Janux Therapeutics Ownership
| JANX Stock | USD 24.04 0.34 1.43% |
Shares in Circulation | First Issued 2020-03-31 | Previous Quarter 56.8 M | Current Value 61.8 M | Avarage Shares Outstanding 38.1 M | Quarterly Volatility 16.1 M |
Janux Stock Ownership Analysis
About 93.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.42. Some equities with similar Price to Book (P/B) outperform the market in the long run. Janux Therapeutics recorded a loss per share of 1.33. The entity had not issued any dividends in recent years. Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager platform technology to treat patients suffering from cancer. The company was incorporated in 2017 and is headquartered in La Jolla, California. Janux Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. To learn more about Janux Therapeutics call David Campbell at 858 751 4493 or check out https://www.januxrx.com.Janux Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Janux Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Janux Therapeutics backward and forwards among themselves. Janux Therapeutics' institutional investor refers to the entity that pools money to purchase Janux Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | T. Rowe Price Associates, Inc. | 2025-03-31 | 1.4 M | State Street Corp | 2025-03-31 | 1.4 M | Citadel Advisors Llc | 2024-12-31 | 1.4 M | Franklin Resources Inc | 2025-03-31 | 1.2 M | Perceptive Advisors Llc | 2025-03-31 | 970.4 K | Geode Capital Management, Llc | 2025-03-31 | 780.9 K | Orbimed Advisors, Llc | 2025-03-31 | 758.6 K | Bank Of America Corp | 2025-03-31 | 749.3 K | Avidity Partners Management Lp | 2024-12-31 | 741.9 K | Ra Capital Management, Llc | 2024-12-31 | 10.4 M | Fmr Inc | 2025-03-31 | 8.9 M |
Janux Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Janux Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Janux Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Janux Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Janux Therapeutics Outstanding Bonds
Janux Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Janux Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Janux bonds can be classified according to their maturity, which is the date when Janux Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3591 Corp BondUS61744YAK47 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| MGM Resorts International Corp BondUS552953CD18 | View | |
| Valero Energy Partners Corp BondUS91914JAA07 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Janux Therapeutics Corporate Filings
F3 | 23rd of May 2025 The report used by insiders such as officers, directors, and major shareholders (beneficial owners holding more than 10% of any class of the company's equity securities) to declare their ownership of a company's stock | ViewVerify |
| 14th of May 2025 Other Reports | ViewVerify | |
8K | 8th of May 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
F4 | 2nd of May 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Janux Stock Analysis
When running Janux Therapeutics' price analysis, check to measure Janux Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Janux Therapeutics is operating at the current time. Most of Janux Therapeutics' value examination focuses on studying past and present price action to predict the probability of Janux Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Janux Therapeutics' price. Additionally, you may evaluate how the addition of Janux Therapeutics to your portfolios can decrease your overall portfolio volatility.